Clinical Edge Journal Scan

Breast cancer: Postmastectomy implant reconstruction increases risk for anaplastic large cell lymphoma


 

Key clinical point: The relative risk for anaplastic large cell lymphoma (ALCL) was significantly increased in women who underwent implant reconstruction after mastectomy for breast cancer (BC) or ductal carcinoma in situ.

Major finding: The relative risk for ALCL (standardized incidence ratio [SIR] 40.9; 95% CI 13.3-95.5) and T-cell lymphoma (SIR 34.8; 95% CI 12.8-75.8) increased significantly after postmastectomy implant reconstruction.

Study details : This study evaluated 56,784 women with ductal carcinoma in situ of the breast (18%) or invasive BC (72%) from the Surveillance, Epidemiology, and End Results 17 database who had undergone postmastectomy implant reconstruction.

Disclosures: This study did not report a source of funding. The authors declared serving as consultants or receiving grants, royalties, licenses, or personal fees from several sources.

Source: Kinslow CJ et al. Risk of anaplastic large cell lymphoma following postmastectomy implant reconstruction in women with breast cancer and ductal carcinoma in situ. JAMA Netw Open. 2022;5(11):e2243396 (Nov 22). Doi: 10.1001/jamanetworkopen.2022.43396

Recommended Reading

Cancer researcher banned from federal funding for faking data in nearly 400 images in 16 grant applications
MDedge Hematology and Oncology
CTC-guided therapy beats physician choice in metastatic breast cancer
MDedge Hematology and Oncology
Breast conservation safe option in multisite breast cancer
MDedge Hematology and Oncology
Exciting advances in HR-positive breast cancer: Top five picks from SABCS
MDedge Hematology and Oncology
Adjuvant chemo tied to better survival in low-risk node-positive breast cancer
MDedge Hematology and Oncology
Structural racism tied to later-stage breast cancer diagnoses
MDedge Hematology and Oncology
Breast cancer diagnoses worse among Hispanics during COVID-19 pandemic
MDedge Hematology and Oncology
Most women with breast cancer elude serious COVID-19 vaccine side effects
MDedge Hematology and Oncology
Long lasting benefit with dose-dense adjuvant chemotherapy in high-risk early BC
MDedge Hematology and Oncology
HR+/HER2− BC: Adjuvant abemaciclib+ET shows sustained positive benefit-risk profile
MDedge Hematology and Oncology